27th Apr 2023 18:13
Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Reports revenue in the year to December 31 trebled to GBP4.5 million from GBP1.5 million a year before. Says net product revenue from sales of Accrufer in the US totalled GBP2.9 million, up from GBP0.1 million while royalty revenue from product sales in Europe reached GBP1.4 million, up from GBP0.9 million. Read More
